Material Agreement

UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549       FORM 8-K       CURRENT REPORT  Pursuant to Section 13 OR 15(d) of The  Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): September 23, 2022       AIKIDO PHARMA INC.   (Exact name of registrant as specified in its charter)   Delaware   000-05576   52-0849320 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   One Rockefeller Plaza , 11th Floor , New York , NY   10020 (Address of principal executive offices)   (Zip Code)    Registrant’s telephone number, including area code: (703) 993-9325   N/A   (Former name or former address, if changed since last report.)       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:     ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value AIKI The Nasdaq Capital Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐           Item 1.01. Entry Into a Material Definitive Agreement.   On September 23, 2022, Dominari Financial, Inc. (“Dominari”), a wholly owned subsidiary of AIkido Pharma, Inc, (the “Company”) entered into a Lease Agreement (the “Lease”) with Trump Tower Commercial LLC, a New York limited liability company.   Pursuant to the Lease, Dominari will rent a portion of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari plans to use the Premises to run its day-to-day operations.   The initial term of the Lease is seven (7) years commencing on the date that possession of the Premises is delivered to Dominari.   Pursuant to the Lease, Dominari will pay rent equal to forty-nine thousand three hundred and sixty-eight dollars per month. Effective for the sixth and seventh years of the Lease, the rent shall increase to fifty-one thousand eight hundred and sixty-eight dollars per month.   The foregoing is a summary of the terms of the Lease, a copy of the Lease will be filed with the Company’s next Quarterly Report on Form 10-Q.     1     SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   Dated: September 29, 2022 AIKIDO PHARMA INC.       By: /s/ Anthony Hayes   Name:  Anthony Hayes   Title: Chief Executive Officer   2